Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23849707 | 0.95 | FOLH1 (0.55) | FOLH1CTSLCTSKCPB1CPB2 | |
| SCHEMBL19065207 | 0.95 | FOLH1 (0.55) | FOLH1CTSLCTSKCPB1CPB2 | |
| SCHEMBL29335184 | 0.91 | CTSB (0.57) | FOLH1CTSLCTSKCPB1CPB2 | |
| SCHEMBL14680621 | 0.87 | CPB1 (0.46) | FOLH1CTSLCTSKCPB1CPB2 | |
| SCHEMBL4330584 | 0.87 | FOLH1 (0.57) | FOLH1ITGB3ITGA2BSIRT2SIRT1 | |
| SCHEMBL31514320 | 0.86 | FOLH1 (0.48) | FOLH1PAX8TDP1 | |
| SCHEMBL31514300 | 0.86 | FOLH1 (0.48) | FOLH1PAX8TDP1 | |
| SCHEMBL14680407 | 0.86 | CPB1 (0.53) | FOLH1CPB1CPB2SIRT2SIRT1 | |
| SCHEMBL29679328 | 0.86 | CTSB (0.48) | FOLH1CTSLCTSKCPB1CPB2 | |
| SCHEMBL19065231 | 0.86 | FOLH1 (0.56) | FOLH1CPB1CPB2PAX8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | FOLH1 43/4885CTSL 1672/4885CTSK 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.